Therapeutic strategies for relapsing–remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343(13):938-52
   PubMed Web of Science ®Google Scholar
• Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747
   PubMed Web of Science ®Google Scholar
• Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17(2):210-18
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338(5):278-85
   PubMed Web of Science ®Google Scholar
• Howell O, Reeves C, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011;134(Pt 9):2755
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell OW, Reeves C, et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010;68(4):477
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Calabrese M, Fisher E, et al. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012;11(12):1082-92
   PubMed Web of Science ®Google Scholar
• Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009;66(9):1144-50
   PubMedGoogle Scholar
• Calabrese M, Rinaldi F, Grossi P, et al. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler 2010;16(10):1220-8
   PubMed Web of Science ®Google Scholar
• Calabrese M, De Stefano N, Atzori M, et al. Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol 2008;255(4):581-6
   PubMed Web of Science ®Google Scholar
• Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353(9157):964-9
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990;300(6725):631-4
   PubMedGoogle Scholar
• Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006;129(Pt 3):595-605
   PubMed Web of Science ®Google Scholar
• Calabrese M, Romualdi C, Poretto V, et al. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann Neurol 2013;74(1):76-83
   PubMed Web of Science ®Google Scholar
• Peterson JW, Bö L, Mörk S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50(3):389-400
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365(23):2188-97
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Serafini B, Rosicarelli B, et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol 2013;72(1):29-41
   PubMed Web of Science ®Google Scholar
• Pomeroy IM, Matthews PM, Frank JA, et al. Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 2005;128(Pt 11):2713-21
   PubMedGoogle Scholar
• Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130(Pt 4):1089-104
   PubMed Web of Science ®Google Scholar
• Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007;64(10):1416-22
   PubMedGoogle Scholar
• Calabrese M, Poretto V, Favaretto A, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012;135(Pt 10):2952-61
   PubMed Web of Science ®Google Scholar
• Calabrese M, Rocca MA, Atzori M, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009;72(15):1330-6
   PubMed Web of Science ®Google Scholar
• Charil A, Filippi M. Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J Neurol Sci 2007;259(1-2):7-15
   PubMed Web of Science ®Google Scholar
• Pirko I, Lucchinetti CF, Sriram S, et al. Gray matter involvement in multiple sclerosis. Neurology 2007;68(9):634-42
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008;7(9):841-51
   PubMed Web of Science ®Google Scholar
• Sastre-Garriga J, Ingle GT, Rovaris M, et al. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology 2005;65(4):633-5
   PubMed Web of Science ®Google Scholar
• Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127(Pt 5):1101-7
   PubMed Web of Science ®Google Scholar
• De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60(7):1157-62
   PubMed Web of Science ®Google Scholar
• Tartaglia MC, Narayanan S, Francis SJ. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol 2004;61(2):201-7
   PubMedGoogle Scholar
• Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 2005;128(Pt 6):1454-60
   PubMed Web of Science ®Google Scholar
• Pérez-Miralles F, Sastre-Garriga J, Tintoré M, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler 2013;19(14):1878-86
   PubMed Web of Science ®Google Scholar
• Ciccone A, Beretta S, Brusaferri F, et al. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008(1):CD006264
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Benedetti MD, Poli S, et al. Azathioprine in multiple sclerosis. Mini Rev Med Chem 2008;8(9):919-26
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol 2007;254:1723-8
   PubMed Web of Science ®Google Scholar
• Massacesi L, Tramacere I, Benedetti MD, et al. Direct comparison of azathioprine and beta interferon efficacy in multiple sclerosis [abstract]. Neurology 2013;80:P01.200
   Web of Science ®Google Scholar
• Havrdova E, Zivadinov R, Krasensky J, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009;15:965-76
   PubMed Web of Science ®Google Scholar
• Stankiewicz JM, Kolb H, Karni A, et al. Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics 2013;10(1):77-88
   PubMed Web of Science ®Google Scholar
• La Mantia L, Milanese C, Mascoli N, et al. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev 2007(1):CD002819
   Google Scholar
• Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013;5:CD002127
   Google Scholar
• Chanvillard C, Millward JM, Lozano M, et al. Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PLoS One 2012;7(6):e39625
   PubMed Web of Science ®Google Scholar
• Axelsson M, Malmeström C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014;20(1):43-50
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43(4):655-61
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43(4):662-7
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995;1(2):118-35
   PubMedGoogle Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352(9139):1498-504
   PubMed Web of Science ®Google Scholar
• Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013;6:CD008933
   PubMed Web of Science ®Google Scholar
• Sättler MB, Demmer I, Williams SK, et al. Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol 2006;201(1):172-81
   PubMed Web of Science ®Google Scholar
• Di Filippo M, Tozzi A, Tantucci M, et al. Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: electrophysiological evidence. Neurobiol Dis 2014;62:387-93
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8(11):987-97
   PubMed Web of Science ®Google Scholar
• Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;61(4):300-6
   PubMed Web of Science ®Google Scholar
• Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247-56
   PubMed Web of Science ®Google Scholar
• Rojas JI, Romano M, Ciapponi A, et al. Interferon Beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev 2010(1):CD006643
   Google Scholar
• Mantia LL, Vacchi L, Rovaris M, et al. Interferon β for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry 2013;84(4):420-6
   PubMed Web of Science ®Google Scholar
• Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000;48(6):885-92
   PubMed Web of Science ®Google Scholar
• Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996;47(6):1463-8
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59(5):679-87
   PubMed Web of Science ®Google Scholar
• Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, et al. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013;19(9):1175-81
   PubMed Web of Science ®Google Scholar
• Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS: multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-704
   PubMed Web of Science ®Google Scholar
• Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-96
   PubMed Web of Science ®Google Scholar
• Jones CK, Riddehough A, Li DKB, et al. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS Trial [abstract]. Neurology 2001;56(Suppl 3):A379
   Google Scholar
• Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Roosendaal SD, Calabrese M, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 2011;76(5):418-24
   PubMed Web of Science ®Google Scholar
• Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler 2012;18(4):418-24
   PubMed Web of Science ®Google Scholar
• Maier K, Kuhnert AV, Taheri N, et al. Effects of GA and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol 2006;169(4):1353-64
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71(2):136-44
   PubMed Web of Science ®Google Scholar
• Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol 2013;260(7):1901-6
   PubMed Web of Science ®Google Scholar
• Weinstein A, Schwid SR, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56(3):319-24
   PubMedGoogle Scholar
• Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 2007;255(1-2):57-63
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-23
   PubMed Web of Science ®Google Scholar
• Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68(17):1390-401
   PubMed Web of Science ®Google Scholar
• Radue EW, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 2010;292(1-2):28-35
   PubMed Web of Science ®Google Scholar
• Rinaldi F, Calabrese M, Seppi D, et al. Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis. Mult Scler 2012;18(12):1760-7
   PubMed Web of Science ®Google Scholar
• Mancuso R, Franciotta D, Rovaris M, et al. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. Mult Scler(2014); doi:10.1177/1352458514538111. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Portaccio E, Stromillo ML, Goretti B, et al. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis–a prospective, non-randomized pilot study. Eur J Neurol 2013;20(6):986-90
   PubMed Web of Science ®Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33(2):91-101
   PubMed Web of Science ®Google Scholar
• Soliven B, Miron V, Chun J. The neurobiology of sphingosine 1-phosphate signalling and sphingosine 1-phosphate receptor modulators. Neurology 2011;76(8 Suppl 3):S9-S14
   PubMed Web of Science ®Google Scholar
• Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010;176(6):2682-94
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-15
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401
   PubMed Web of Science ®Google Scholar
• Radue EW, O’Connor P, Polman CH, et al. FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 2012;69(10):1259-69
   PubMedGoogle Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014;74(6):659-74
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-303
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH, et al. BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372(9648):1463-72
   PubMed Web of Science ®Google Scholar
• Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012;341(1):274-84
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134(Pt 3):678-92
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
   PubMed Web of Science ®Google Scholar
• Wegner C, Stadelmann C, Pförtner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;227(1-2):133-43
   PubMed Web of Science ®Google Scholar
• Jolivel V, Luessi F, Masri J, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013;136(Pt 4):1048-66
   PubMed Web of Science ®Google Scholar
• Aharoni R, Saada R, Eilam R, et al. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2012;251(1-2):14-24
   PubMed Web of Science ®Google Scholar
• Toubi E, Nussbaum S, Staun-Ram E, et al. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol 2012;251(1-2):45-54
   PubMed Web of Science ®Google Scholar
• Thöne J, Ellrichmann G, Seubert S, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 2012;180(1):267-74
   PubMed Web of Science ®Google Scholar
• Ruffini F, Rossi S, Bergamaschi A, et al. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler 2013;19(8):1084-94
   PubMed Web of Science ®Google Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366(11):1000-9
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. on behalf of the ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2014;85(8):851-8
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing–remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-87
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li DKB, Riddehough A, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Lyon, France; 2012
   Google Scholar
• Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001;3:137-43
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009;128(2):260-70
   PubMed Web of Science ®Google Scholar
• Thompson SA, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2009;30(1):99-105
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380(9856):1819-28
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380(9856):1829-39
   PubMed Web of Science ®Google Scholar
• Arnold DL, et al. Effect of Alemtuzumab vs. Rebif® on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11.006). Neurology 2012; 78 (Meeting Abstracts 1): S11.006
   Google Scholar
• Zipp F, Gold R, Wiendl H. Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies? JAMA Neurol 2013;70(12):1569-74
   PubMed Web of Science ®Google Scholar
• Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014;383:2213-21
   PubMed Web of Science ®Google Scholar
• De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74(23):1868-76
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Calabrese M, Benedetti MD, et al. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers 2013;35(6):687-99
   PubMed Web of Science ®Google Scholar